Literature DB >> 10459349

Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas.

L Kluwe1, R E Friedrich, V F Mautner.   

Abstract

Neurofibromatosis 1 (NF1) is an autosomal dominant disorder with a complex variety of clinical symptoms. Genetic alteration of the NF1 gene on 17q11.2 is the disease. Neurofibromas of the peripheral nervous system are one main manifestation. A variant of neurofibroma is the plexiform neurofibroma which can be found in about 30% of NF1-patients, often causing severe clinical symptoms. In this study, we examined 14 such tumors from 10 NF1-patients for allele loss of the NF1 gene (LOH: loss of heterozygosity) using four intragenic polymorphic markers. Loss of heterozygosity was found in eight tumors from five patients, and suspected in one additional tumor from another patient. This finding suggests that loss of the second allele, and thus inactivation of both alleles of the NF1 gene, is associated with the development of plexiform neurofibromas. The 14 plexiform neufibromas were also examined for mutation in the TP53 gene by screening exons 5 through 8 using temperature gradient gel electrophoresis. No mutation was found in any of the tumors.

Entities:  

Mesh:

Year:  1999        PMID: 10459349     DOI: 10.1016/s0165-4608(99)00006-0

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  15 in total

1.  NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors.

Authors:  A Perry; K A Roth; R Banerjee; C E Fuller; D H Gutmann
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 2.  Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Authors:  Brigitte C Widemann
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

3.  Evaluation of molecular genetic alterations associated with tumor progression in a case of gliomatosis cerebri.

Authors:  Stefan Braeuninger; Regine Schneider-Stock; Elmar Kirches; James M Powers; David N Korones; Christian Mawrin
Journal:  J Neurooncol       Date:  2006-09-06       Impact factor: 4.130

4.  Decreased bone mineral density in patients with neurofibromatosis 1.

Authors:  Marga Lammert; Martin Kappler; Victor-Felix Mautner; Kurt Lammert; Stephan Störkel; Jan M Friedman; Derek Atkins
Journal:  Osteoporos Int       Date:  2005-06-30       Impact factor: 4.507

5.  Expression analysis of genes lying in the NF1 microdeletion interval points to four candidate modifiers for neurofibroma formation.

Authors:  B Bartelt-Kirbach; M Wuepping; M Dodrimont-Lattke; D Kaufmann
Journal:  Neurogenetics       Date:  2008-10-11       Impact factor: 2.660

6.  Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types.

Authors:  Gill Spurlock; Siân Griffiths; Jeremy Uff; Meena Upadhyaya
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

7.  Skin-derived precursor cells as an in vitro modelling tool for the study of type 1 neurofibromatosis.

Authors:  Araika Gutiérrez-Rivera; Haizea Iribar; Anna Tuneu; Ander Izeta
Journal:  Stem Cells Int       Date:  2012-04-01       Impact factor: 5.443

8.  Peripheral nerve sheath tumors of the upper extremity and hand in patients with neurofibromatosis type 1: topography of tumors and evaluation of surgical treatment in 62 patients.

Authors:  Reinhard E Friedrich; Caroline Diekmeier
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2017-12-05

9.  Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.

Authors:  Sidra Ahsan; Yubin Ge; Michael A Tainsky
Journal:  Oncotarget       Date:  2016-08-30

10.  TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.

Authors:  Gun-Hoo Park; Su-Jin Lee; Hyunee Yim; Jae-Ho Han; Hyon J Kim; Young-Bae Sohn; Jung Min Ko; Seon-Yong Jeong
Journal:  Oncol Rep       Date:  2014-08-04       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.